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Objective: To determine whether the use of cannabis improves pain control and/or reduces the 
amounts of opioids needed to control pain in adults with chronic pain.   
Methods: A systematic literature review of research conducted from the past five years. Five 
databases were searched, resulting in 14 peer-reviewed articles relevant to the objective.   
Results: The majority of the literature reviewed demonstrated the use of cannabis by adults with 
chronic pain resulted in better pain control and/or fewer opioids required to control pain in this 
population. The two articles which contradicted these findings only evaluated illicit, not medical, 
cannabis use by individuals with chronic pain.   
Conclusions: Cannabis should be considered as an alternative or adjunct to opioid therapy in 
adults with chronic pain. Changes in patient and provider education about cannabis as a therapy 
for chronic pain are necessary. The classification of cannabis as a Schedule I controlled 
substance by the federal government complicates research, public perception, and patient access 
and should be re-evaluated. Further research is indicated in determining the specific types, 
strains, and methods of ingestion that are most effective in this population; the sub-types of pain 
that are improved with cannabis; what the adverse effects of cannabis use in this population are; 
and what barriers exist for providers in recommending cannabis as a treatment option. Evidence 
from RCTs, particularly comparing cannabis to opioids, is lacking yet difficult to obtain due to 
federal and ethical limitations.   
 
Keywords: cannabis, marijuana, opioid(s), opiate(s), chronic pain, intractable pain, pain  
control, prescribed, prescription(s) 
Cannabis as an Opiate Substitute for Adults with Chronic Pain:  
A Systematic Literature Review 
 From 1999-2018, nearly 450,000 individuals died from an opioid overdose in the United 
States, including from the use of both prescription and illicit opioids (Centers for Disease 
Control and Prevention [CDC], 2020). In 2019 alone, almost 50,000 individuals died from 
opioid-involved overdoses in the United States (National Institutes of Health [NIH], 2021).  
Pharmaceutical companies assured health care providers that prescription opioids such as 
oxycodone were not addictive, leading to exponential increases in the prescribing of these 
medications for moderate and severe pain beginning in the late 1990s (CDC, 2020). Even after 
the CDC released new guidelines for providers in 2016 intended to reduce the number of opioids 
prescribed, 191 million opioid prescriptions were still written in 2017 (CDC, 2020). As public 
interest in reducing opioid prescriptions has increased, so have the number of states allowing the 
legal use of cannabis to treat a range of medical conditions, including chronic pain. Today, 31 of 
the 36 states with legalized cannabis use allow cannabis to be used to treat chronic pain, although 
the language and restrictions vary from state-to-state (Medical Marijuana Project [MMP], 2021).  
Fifteen states allow for adult use of cannabis for any reason, including recreationally and many 
individuals who purchase adult-use cannabis report using it to control pain (MMP, 2021). In the 
context of this newly expanded access to cannabis for pain control, the CDC’s recommendation 
that providers consider other available options for treating chronic pain (Dowell et al., 2016) 
supports investigating the efficacy of cannabis in controlling chronic pain and evaluating its 




 CDC guidelines define ‘chronic pain’ as pain that has been present for greater than three 
months or past the time of normal tissue healing (Dowell et al., 2016). Data from the National 
Health Interview Survey indicated that in 2019, 20.4% of adults in the United States had chronic 
pain, and 7.4% of adults had ‘high-impact’ chronic pain frequently limiting life or work activities 
in the past 3 months (Zelaya et al., 2020). Chronic pain and high-impact chronic pain is 
associated with decreased quality of life; increased rates of depression, anxiety, and insomnia; 
lost work productivity and increased opioid use dependence (Zelaya et al., 2020). Survey data 
indicated that women, adults over the age of 65, and individuals living in rural communities were 
more likely to suffer from chronic pain than others (Zelaya et al., 2020). 
Many patients affected by chronic pain are prescribed opioid analgesics. Of patients with 
chronic pain who are prescribed opioids, approximately 21-29% will misuse these opioids, 4-6% 
will transition to heroin use, and 8-12% will develop an opioid use disorder (NIH, 2021). In 
2017, 1.7 million adults had a substance use disorder related to prescription opioid pain relievers 
(NIH, 2021). Repeated use of opioids over time increases the risk of developing an opioid use 
disorder (HHS, 2016). Even patients using opioids appropriately as prescribed are subject to a 
wide range of side effects including constipation, nausea, vomiting, sexual dysfunction, sedation, 
dizziness, physical dependence, withdrawal syndrome, and respiratory depression (Benyamin et 
al., 2008; Woodbury, 2015). Many patients develop tolerance to opioids over time and are 
prescribed increasingly larger doses. Some patients paradoxically experience increased pain on 
the higher doses of opioids, a phenomenon referred to as opioid-induced hyperalgesia 
(Woodbury, 2015). Contrary to public perception of opioids as the gold standard for pain relief, 
the CDC stated in its opioid prescribing guidelines for chronic pain that “Evidence on long-term 
opioid therapy for chronic pain outside of end-of-life care remains limited, with insufficient 
evidence to determine long-term benefits versus no opioid therapy, though evidence suggests 
risk for serious harms that appears to be dose-dependent,” (Dowell et al., 2016). The first 
recommendation from the CDC within these new guidelines is that “Nonpharmacologic therapy 
and non-opioid pharmacologic therapy are preferred for chronic pain…if opioids are used, they 
should be used in conjunction with nonpharmacologic and non-opioid pharmacologic therapy, as 
appropriate,” (Dowell et al., 2016).   
The relatively high risk-benefit ratio of using opioids for chronic pain requires primary 
care providers to re-evaluate options for controlling pain in this population. In early 2016 when 
the CDC published its recommendations on the prescription of opioids for providers, only 25 
states and the District of Colombia provided for the legal use of medical cannabis (Medical 
Marijuana Project, 2021). Today, 31 states include a provision for the legal use of medical 
cannabis for severe or chronic pain. Even though most states now allow for legalized medical 
cannabis to control chronic pain, cannabis remains a Schedule I controlled substance under 
Federal Law, placing it in the same class as drugs deemed to have no medical benefit and a high 
risk of abuse such as heroin and LSD. Prescription opioids, by contrast, are classified as 
Schedule II-V drugs which confers some medical benefit at the expense of varying risks of 
abused. Despite its Schedule I classification, 15 states currently allow for legalized recreational 
use of cannabis by adults. Many adults in these states purchase cannabis from recreational 
dispensaries to be used medicinally, akin to purchasing ibuprofen over the counter instead of 
obtaining a prescription for ibuprofen due to ease of access.   
Cannabis, also known as ‘marijuana’, refers to the leafy plants Cannabis sativa and 
Cannabis indica. Cannabis grows naturally in much of the world and has been used for various 
medicinal purposes for thousands of years (Borgelt et al., 2013). The United States 
Pharmacopeia included it as a medical compound from 1851 until it was removed in 1942, five 
years after it was criminalized, despite objections from the American Medical Association 
(Borgelt et al., 2013). Cannabis contains a mixture of chemicals known as cannabinoids.  
Examples of cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the 
cannabinoid typically found in the greatest quantity in cannabis and is known to be psychoactive. 
It binds to two types of cannabinoid receptors (C1 and C2) in the brain. It is thought that 
analgesia created by THC’s binding to the endocannabinoid system in the brain may be the result 
of several different mechanisms including modulation of neuronal activity, effects on descending 
pain pathways, and inhibition of prostaglandin synthesis (Borgelt et al., 2013). The mechanism 
by which CBD works is not completely known, but it is known that it does not bind to the C1 or 
C2 receptors like THC and is hypothesized to counteract some of the psychogenic effects of 
THC (Borgelt et al., 2013).  
There are currently no cannabis products that have been approved for medical use by the 
U.S. Food and Drug Administration (Food and Drug Administration [FDA], 2021). Dronabinol 
and nabilone are oral medications containing synthetically derived THC that are FDA-approved 
prescription medications for nausea and vomiting related to chemotherapy. Dronabinol has also 
been approved for anorexia and wasting from AIDS, due to its appetite-enhancing effect. The 
only other related product that is FDA-approved is Epidolex, a purified form of CBD (without 
THC), indicated for specific severe seizures in children (FDA, 2021). None of these products are 
FDA-approved for the treatment of acute or chronic pain (FDA, 2021). Although research has 
been done on the above cannabinoids as to their efficacy in relieving pain, for the purpose of this 
review we will limit further discussion exclusively to include only cannabis.   
The juxtaposition of the federal classification of cannabis as a Schedule I controlled 
substance and the increasing availability of legalized medical cannabis as an option for treatment 
of chronic pain merits investigation into whether evidence supports its use for this purpose.  
Primary care providers, including nurse practitioners, see many patients presenting with chronic 
pain in their day-to-day practice. Primary care providers also serve as stewards of public health 
who are being urged to assist in the opioid crisis by re-evaluating their prescribing practices 
relating to opioids. A review of pertinent literature will aim to answer the clinical question: In 
adults with chronic pain, does the use of cannabis improve pain control and reduce the amounts 
of opioids required to control pain? The intent of this review is to provide primary care 
providers, including nurse practitioners, with evidence-based recommendations for their patients 
presenting with chronic pain regarding treatment with medical cannabis.   
Methods  
Databases and Search Strategies   
An extensive literature search was completed between the dates of 10/15/2020 and 
11/20/20. Both PubMed and EBSCO Host Databases were included. Within EBSCO Host, the 
Academic Search Premier database, CINAHL Plus with Full-Text database, Cochrane Central 
Register of Controlled Trials database and the Cochrane Database of Systemic Reviews were 
selected for the searches. The searches were restricted to full-text journal articles in the English 
Language from the past five years. Specific search restrictions for each database and the general 
subjects covered by each database are included in Table 1 of the appendix. 
 Details on the search terms used and resulting hits in each database are included in Table 
2 of the appendix. Titles of articles which were included in searches with less than 25 hits were 
scanned and duplicate titles were eliminated. Of the 28 individual articles remaining, the titles 
and abstracts were reviewed to see if the article met inclusion or exclusion criteria.   
Inclusion and Exclusion Criteria 
 To most effectively answer the clinical question posed above, pre-determined inclusion 
criteria required that the article either: a) examined the effects of cannabis consumption on 
chronic pain, b) examined the relationship between cannabis use and prescription opioid use in 
patients with chronic pain, or c) examined the relationship between cannabis use and the 
amounts of opioids prescribed by providers. Exclusion criteria included a) illicit or non-
prescription use of opioids as a variable, or no specification as to whether the opioid was 
prescribed, b) a study population that included individuals < 18 years of age, c) no inclusion of 
cannabis or its use in the study, d) investigation of cannabis or opioid misuse, e) opinion articles, 
f) study or policy proposals. Table 3 of the appendix details specific application of inclusion and 
exclusion criteria to each of the 28 articles. Of these, 14 met criteria for inclusion in the final 
literature review.   
Literature Review Process 
 The full text of the selected 14 articles was reviewed and analyzed to extrapolate what 
populations were being studied, what variables were being investigated, what instruments were 
utilized, pertinent clinical findings, implications for practice, and the level of evidence involved.  
Table 4 of the appendix summarizes each of these 14 articles in detail. 
Methodological Assessment 
 Several databases were searched using multiple relevant search terms in various 
combinations, producing articles which all helped answer the clinical question posed above.  
However, this literature review was subject to certain limitations. In wishing to retrieve the most 
recent data, the search timeframe was limited to articles published within the last five years.  
This may have resulting in missing other pertinent research, albeit older, that could support or 
refute the conclusions. Initially, the review was going to be limited to only medicinal cannabis, 
but in reading some of the articles it was apparent there were subsets of individuals who would 
either qualify for medical cannabis but lived in one of the 15 states where recreational cannabis 
was legal and purchased it at the recreational dispensaries instead or those that self-substituted 
illicit cannabis for prescription opioids. Hence, the criteria for cannabis to be strictly ‘medical’ 
was eliminated. Searching more databases may have yielded more articles, as would have not 
limiting the search to full text only. This review was completed by one author and having a 
second author validate the above searches, articles, and inclusion/exclusion criteria would better 
control for potential bias and enhance the validity of the findings, consistent with established 
standards for systematic reviews.   
Literature Review 
Study Characteristics 
 Most of the studies evaluated were cross-sectional cohort studies or secondary data 
analyses of cross-sectional cohort studies. One study was a quasi-experimental difference-
within-differences study, one was a historical cohort study, one study was a secondary data 
analysis of a prospective cohort study, and one study was a case report (n=1). Three studies were 
qualitative in nature, describing the experience of individuals with chronic pain and cannabis. 
Due to the design of the studies retrieved, the highest level of evidence found was the inclusion 
of several cross-sectional studies that were Level IV (Melnyk & Fineout-Overholt, 2015). All the 
studies reviewed would be considered Level IV, except for the three qualitative studies and the 
individual case report, all of which were Level VI (Melnyk & Fineout-Overholt, 2015). One 
relevant systemic review and meta-analysis on cannabinoids (Level I) was found while searching 
the Minnesota Department of Health website for additional resources (Whiting et al., 2015).  
However, because this meta-analysis and systemic review explored all cannabinoids and not just 
cannabis, only the information included on the studies involving cannabis was considered so the 
overall meta-analysis was not applicable.   
Types of Research 
 While conducting the literature review, it became apparent that the clinical question 
posed above could be broken down into two related components. Eight of the articles examined 
whether cannabis helped control pain in individuals with chronic pain. Thirteen of the articles 
examined whether cannabis use impacted the amount of prescription opioids that were either 
used or prescribed for adults. All eight articles which examined whether cannabis helped control 
pain also examined whether cannabis use was related to prescription opioid use, so there was 
overlap among these eight articles. One qualitative article did not fit directly into either of the 
above divisions but provided complementary insight into decreased opioid prescriptions driving 
the desire to utilize medical cannabis for a group of adults with chronic pain and was retained for 
this reason.   
Populations Studied 
The populations studied ranged in number from a case study of an individual with acute 
on chronic pain (Meng et al., 2016) to a secondary data analysis of 4,840,562 individual records 
of commercially insured adults, of which a subgroup of adults with chronic pain that represented 
approximately 30% of that number were included (Shah et al., 2019). Eight of the cross-sectional 
quantitative studies had an n>1000, while the three qualitative studies had n=15 (Sinha et al., 
2019), n=21 (Gill & Young, 2019), and n=200 (Zaller et al., 2015). 
The populations studied fall into four categories: 1) Cannabis users whose reasons for 
using were studied, 2) adults with chronic pain who were using cannabis and prescription opioids 
together, 3) Medicare patients with chronic pain, and 4) Medicaid patients with opioid 
prescriptions. One study only included adults with chronic pain from sickle-cell anemia (Sinha et 
al., 2019), and two studies included only adults with HIV and chronic pain (Merlin et al., 2019, 
Sohler et al., 2018). The single case study focused on an adult male who had diagnoses of acute 
and chronic pain with long-standing opioid use (Meng et al., 2016). 
Research Synthesis 
Population of Interest 
Most of the studies reviewed explicitly limited the population under investigation to 
adults with chronic pain. Recall that chronic pain is considered by the CDC to be pain that has 
been present for greater than three months or past the time of normal tissue healing (Dowell et 
al., 2016), and that in 2019 one-fifth of the US population suffered from chronic pain (Zelaya et 
al., 2020). The individuals who were classified as having chronic pain for the purposes of these 
studies had a variety of underlying diagnoses, ranging from individuals with chronic low back 
pain (Vigil et al., 2017) to individuals affected by sickle cell disease (Sinha et al., 2019) and HIV 
(Merlin et al., 2019; Sohler et al., 2018). Some of the studies inferred chronic pain from patients 
having prescriptions for opioids (Ishida et al., 2019; Wen & Hockenberry, 2018). The variety of 
conditions which could cause chronic pain are numerous and are not differentiated in most of the 
studies reviewed. The Minnesota Department of Health, for example, lists 24 primary symptoms 
experienced by individuals certified for intractable pain who participated in the medical cannabis 
program between Aug 1, 2016 and December 31, 2016 and notes that 15.3% of patients enrolled 
in the program were concurrently certified for at least one additional condition (Minnesota 
Department of Health [MDH], n.d.a). However, all the studies either involved adults with a 
diagnosis of chronic pain, adults who self-identified as having chronic pain, or adults who were 
taking cannabis or prescription opioids for pain.   
Types of Cannabis 
 This review was limited to cannabis, however, within the definition of cannabis is a high 
degree of variability regarding THC: CBD ratio, strain, method of ingestion, and whether the 
cannabis is used legally or illegally. Only one study investigated which types and strains were 
most favored by individuals with chronic pain. Baron et al. (2018) reported that individuals with 
chronic pain preferred hybrid (37%), indica (25.4%) and sativa (20.2%) types, all of which have 
a high ratio of THC: CBD. By contrast, the CBD dominant types were only preferred by 8.2% of 
the chronic pain patients, and balanced types containing equal ratios of CBD and THC were also 
preferred by 8.2% (Baron et al., 2018). The preferred cannabis strains out of the 42 options 
reported by the chronic pain subset were OG Shark (hybrid type), CBD House Blend (CBD 
dominant type), and Pink Kush (hybrid type) (Baron et al., 2018). These patients were all 
participants in one of Canada’s national medical marijuana programs, Tilray, and the results 
highlight how many options exist for users of “medical cannabis.”   
 The propensity toward high THC: Low CBD ratio is consistent with data from the state 
of Minnesota’s medical cannabis program. For the first five months that intractable pain was 
certified as a qualifying condition, 57% of purchases were for “very high” THC: CBD products 
(MDH, n.d.a). This was followed by 33% of purchases being for products with a balanced (1:1) 
THC: CBD ratio (MDH, n.d.a). Notably, several of the other studies included evaluated 
recreational or illicit cannabis use, where the specific type or strain would likely be unknown.   
The same data set from the MDH also included information on the method of how 
medical cannabis was ingested. 54% of purchases were for inhaled cannabis, 39% were for oral 
cannabis, with only 6% for oromucosal and 0.6% for topical preparations (MDH, n.d.a). A 
survey of 200 adults using medical cannabis at a Rhode Island dispensary revealed the vast 
majority smoked (74%) or used vaporized preparations (17%) (Zaller et al., 2015). Nine of the 
other studies explicitly noted differences in the method of use.   
Some of the studies evaluated the use of cannabis in a non-medical context. This included 
illicit use (Campbell et al., 2018, Ishida et al., 2019, Meng et al., 2019, Sohler et al., 2018) and 
use of cannabis in Colorado at an adult-use dispensary without a prescription (Bachhuber et al., 
2019). The remainder of the studies evaluated only medical cannabis in their analyses.   
Control of Pain  
 Of the eight studies which examined the relationship between cannabis use and chronic 
pain, six found that cannabis use improved pain control and two found that cannabis use had no 
positive effect on pain control. Cannabis use was evaluated both in the context of medical 
(prescribed) and recreational (adult) use, as some patients reported using cannabis which was not 
medically prescribed for symptom control.   
 Bachhuber et al. (2019) surveyed 1,000 adults purchasing cannabis at a recreational 
dispensary in Colorado. Recreational use of cannabis is legal for adults in Colorado. Of the 
adults surveyed, 65% reported taking cannabis for pain relief and 74% reported taking cannabis 
to help with sleep (Bachhuber et al., 2019). Within the cannabis users taking cannabis for pain, 
80% rated it as very or extremely helpful in controlling their pain (Bachhuber et al., 2019).  
Difficulty sleeping can be a consequence of chronic pain, and of the users reporting taking 
cannabis to promote sleep, 83% found it to be very or extremely helpful for sleep.   
 Adults who were prescribed medical cannabis were questioned as to their underlying 
conditions at a dispensary in Rhode Island (Zaller et al., 2015). The most common reason for use 
among the 200 patients surveyed was chronic pain management, with 69% of patients reporting 
experiencing chronic pain at baseline (Zaller et al., 2015). 85% of these patients reported that 
medical cannabis resulted in feeling “much better” (Zaller et al., 2015) 
Of 21 individuals surveyed through a medical cannabis delivery service in California, 10 
reported using it for chronic pain (Gill & Young, 2019). One theme that emerged during their 
interviews was that cannabis was often used due to clinical failure, defined as the inability of 
other medical treatments to control their pain, or to control symptoms such as insomnia that other 
treatments did not help with (Gill & Young, 2019). Another theme endorsed by this cohort was 
the lack of side effects from using cannabis for pain control compared to other treatments, 
including opioids (Gill & Young, 2019). In the case study of a 57-year-old man who suffered 
from a complex pain syndrome and then received a liver transplant, his pre-transplant VAS 
global pain scores were rated as 5-6/10 with scheduled prescription opioids to control pain. Post-
operatively his VAS pain scores were 5-8/10, requiring escalating doses of opioids. After adding 
medical cannabis to his pain management profile, his VAS scores averaged 4/10 five months 
post-operatively, while on a lower average dose of opioids than pre-operatively (Meng, 2016). A 
dramatic reduction in his neuropathic pain scores (hot-burning 1/10, pain caused by light touch 
3/10) and continuous pain descriptors (throbbing, gnawing) were noted (Meng, 2016), although 
his intermittent pain descriptors (shooting, stabbing, splitting, and sharp) did not change and he 
had developed new neuropathic pain descriptors (numbness, tingling) that were not present prior 
to his post-operative discharge. He also reported the cannabis helped with sleep, nausea, and 
general malaise (Meng et al., 2015).   
Out of 9,003 respondents answering a survey about individual perceptions and use of 
cannabis, 486 adults reported using both cannabis and regular use of prescription opioids for pain 
within the last year (Ishida et al., 2019). The most common reason for substitution of opioids for 
cannabis by this subgroup were better control of pain (36%), fewer side effects (32%) and fewer 
withdrawal symptoms (26%) (Ishida et al., 2019). While these individuals did not have a specific 
diagnosis of chronic pain, their regular use of prescription opioids for pain would imply that they 
experienced some degree of chronic pain. Survey responses by 37 chronic pain patients enrolled 
in the New Mexico Cannabis Program (MCP) who were regular users of medical cannabis 
indicated that they experienced a statistically significant reduction (p<0.001) in pain levels from 
pre-enrollment to one year post enrollment with a mean change of -3.4 on a pain scale from 0-10 
(Vigil et al., 2017). These patients all were being treated for musculoskeletal pain, with back 
pain as the predominant condition (Vigil et al., 2017). On a follow up survey completed by 23 
out of the 37 patients to assess quality-of-life indicators, most patients surveyed also reported 
improvements in activity levels, social life, ability to concentrate, and overall quality-of-life 
(Vigil et al., 2017). None of the 23 respondents believed that using cannabis as a treatment for 
pain had negative effects on any of the quality-of-life indicators (Vigil et al., 2017).   
A systematic review and meta-analysis of cannabinoids for medical use was not found 
during the literature search, likely because the topic was the broader class of cannabinoids and 
not limited to cannabis (Whiting et al., 2015). However, this information was discovered in 
researching the Minnesota Department of Health website for information on the state’s medical 
cannabis program. Although the findings of the systematic review and meta-analysis 
demonstrated that there was moderate-quality evidence to support the use of cannabinoids for the 
treatment of chronic pain (Whiting et al., 2015), for the purpose of this literature review only the 
data from the single study involving cannabis was reviewed. This study showed pain was 
improved for chronic pain patients who used cannabis. Compared to the other studies included in 
the meta-analysis that used cannabinoids other than cannabis, the study involving cannabis 
showed the highest degree of improvement following use (Whiting et al., 2015). This was 
measured as the average number of patients reporting a reduction in pain >30% (OR, 3.43[95% 
CI, 1.03-11.48]) compared to placebo (n=50) (Whiting et al., 2015).   
As explained above, the Minnesota Department of Health website was searched to find 
information on the medical cannabis program in Minnesota. Chronic pain was added as a 
qualifying condition for medical cannabis in Minnesota in 2020, and prior to that, intractable 
pain had been a qualifying condition since 2016 (MDH, 2019a). Intractable pain was previously 
defined by state law as pain “whose cause cannot be removed and, according to generally 
accepted medical practice, the full range of pain management treatments appropriate for the 
patient have been used without adequate result or with intolerable side effects,” (MDH, n.d.b).  
The expansion of medical cannabis to include chronic pain has only been in effect since August 
1, 2020, so no data is yet available on the experiences of this population. However, state health 
commissioner Jan Malcolm stated: 
Minnesota’s medical cannabis program tracks patient experiences so we can learn about 
the real-world benefits and downsides of using medical cannabis for various conditions.  
The generally positive experience patients have had using medical cannabis to treat 
intractable pain prompted us to add chronic pain as a qualifying condition. (MDH, 2019a) 
. 
 Between the time intractable pain was added as a condition in August 2016 and when the 
most recent survey data was available in June 2017, 29% of the 4060 patients receiving cannabis 
for intractable pain experienced a > 30% decrease in pain from baseline within the first four 
months in the program, and 36% of these who experienced a > 30% decrease in pain were able to 
maintain that level after 4 months, or 11% were able to achieve and maintain a >30% decrease in 
pain for 4 months or longer (MDH, 2019b). However, for other related symptoms, intractable 
pain patients who reported moderate or severe symptoms of anxiety, lack of appetite, depression, 
disturbed sleep, fatigue, nausea, and vomiting saw much greater increases in experiencing a 30% 
improvement in these symptoms for 4 months or longer (MDH, 2019b). Thirty-four percent had 
> 30% improvement in anxiety, 34% maintained improvement of appetite, 37% for depression, 
32% saw continued improvement of insomnia, 23% of fatigue, 40% for nausea and 50% for 
vomiting (MDH, 2019b). When intractable pain patients were administered the PEG scale to 
assess Pain Intensity, Enjoyment, and General Activity, 22% of patients experienced and 
maintained some degree of improvement in their composite score for greater than four months 
(MDH, 2019b). For each subset of the PEG scale, 17% of intractable pain patients experienced 
and maintained some improvement in pain intensity, 25% experienced and maintained some 
improvement in life enjoyment experience, and 26% experienced and maintained some 
improvement in general activity interference (MDH, 2019b).   
 A separate report was compiled by the Minnesota Department of Health (n.d.a) that 
summarized the experience of intractable pain patients enrolled in the Medical Cannabis 
Program (MCP) during the first five months that intractable pain was a qualifying condition in 
Minnesota from August 1, 2016 to December 31, 2016. A total of 2,290 patients were enrolled in 
the MCP for intractable pain during this timeframe (MDH, n.d.a). Fifty-four percent of patients 
responded to initial baseline surveys and follow-up surveys six months after certification (MDH, 
n.d.a). The patient self-reported PEG and symptom scores in this report mirrored the results 
described above which included an additional six months of data (MDH, n.d.a). However, a 
“very high or high” level of benefit from medical cannabis was reported by 61% of patients 
responding. Only 10% of patients believed they experienced “little or no benefit” from the 
medical cannabis. Though a decrease in pain severity was the benefit mentioned most often by 
patients (64%), improvement in sleep, reductions in anxiety, reduction of other medications and 
associated side effects improved mobility and function and improvement of other indicators of 
quality of life were all mentioned as secondary benefits of medical cannabis (MDH, n.d.a).   
 This MDH report (n.d.a) also surveyed all the health care practitioners caring for 
intractable pain patients enrolled in the MCP, of which 40% responded. They reported that 41% 
of the 489 patients they cared for in the MCP program had a >30% reduction in their pain score 6 
months after enrolling in the MCP (MDH, n.d.a) using the same pain scoring system prior to 
enrollment in the MCP and at six months afterwards. Forty-three percent of providers believed 
their patients experienced a “very-high or high” level of benefit from the medical cannabis, with 
only 24% believing their patients experienced “little or no” benefit.   
 In contrast to the above studies and reports, a four-year prospective study in Australia 
(The Pain and Opioids In Treatment [POINT] study) found that in a sample of 1,514 non-cancer, 
chronic pain patients who were prescribed opioids, those who reported using cannabis had 
greater pain and lower self-efficacy in managing pain scores, and found no evidence that 
cannabis use reduced pain severity (Campbell et al., 2018). Likewise, Merlin et al. (2019) found 
that in a sample of 433 people living with HIV and chronic pain, the 120 who reported also using 
non-medical cannabis in the past three months did not experience a change in their pain severity 
with increasing or decreasing their cannabis use during the timeframe.  Individuals who had used 
marijuana in the past three months were also more likely to report symptoms of anxiety and 
depression (Merlin et al., 2019). The most common pain locations for this cohort were low back 
and hands/feet (Merlin et al., 2019). Both the Campbell et al. (2018) and Merlin et al. (2019) 
studies investigated non-medical cannabis use, as cannabis was illegal for all purposes, including 
medical, in Australia during the years the POINT study took place. Using cannabis for medical 
purposes was explicitly excluded from the Merlin et al. (2019) study.  
Use of Opioids 
 Like the results for whether cannabis improved pain control or not, 11 of the 13 studies 
found the use of cannabis resulted in decreased amounts of opioids used or prescribed to control 
pain. Two studies found no such relationship between the cannabis and opioids. These 13 studies 
were designed to either allow patients to self-report cannabis use and concurrent prescription use 
or to compare the amount of opioid prescribing in states without medical cannabis laws to states 
providing for medical cannabis for chronic pain.  
 Bachhuber et al. (2019) found in their survey of 1,000 adult-use cannabis customers at a 
dispensary in Colorado that among the 65% of those who reported using cannabis for pain relief, 
88% of those prescribed opioids for pain had either decreased or stopped using opioids since 
initiating the use of cannabis. In their survey of medical cannabis users at a dispensary in Rhode 
Island, Zaller et al., (2015) found that 55% of the 200 users studied had substituted medical 
cannabis for prescription pain relievers, including opioids. Of those endorsing substitution, 92% 
reported fewer unwanted side-effects from medical cannabis compared to traditional prescription 
pain medications, including opioids (Zaller et al., 2015). Gill and Young (2018) found in their 
interviews with patients using a mobile medical cannabis delivery service in California that 
seven out of the ten individuals who were prescribed cannabis for chronic pain had stopped using 
their prescription pain relievers completely. All the medications referenced were opioids, with 
ibuprofen as the only exception (Gill & Young, 2018). Six of these patients stopped using 
prescription analgesics due to the undesirable side effect profile and one patient had become 
addicted to their prescription pain reliever and decided to stop (Gill & Young, 2018). Themes 
that emerged during their interviews included a distrust of the medical field, including physicians 
and pharmaceutical drugs, and use of cannabis to treat addiction to prescription opioids (Gill & 
Young, 2018).   
 In a survey of 2,032 patients enrolled in Tilray, one of Canada’s nationally run Medical 
Cannabis Programs, chronic pain was the primary diagnosis for 29.4% of the patients (Baron et 
al., 2018). Of this subset of chronic pain patients, 53% reported substituting cannabis for 
prescription drugs, with opioids representing 73% of the medications substituted (Baron et al., 
2018). Lucas et al. (2019) analyzed responses from the entire cohort of 2,032 patients, regardless 
of primary diagnosis, and found that the most common substitution of cannabis was for 
prescription drugs (69%), and of those prescription drugs, 35% were opioids. Within the patients 
(n=610) who reported substituting cannabis for prescription opioids, 59% had stopped using 
opioids entirely (Lucas et al., 2019).   
These findings are consistent with the Ishida et al. (2019) study: Among the 486 users of 
both prescription opioids for pain and cannabis, 41% reported a decrease or cessation in 
prescription opioid use. The case study of a 57-year-old man suffering from complex generalized 
abdominal pain prior to liver transplantation illustrated a dramatic reduction in his post-operative 
opioid requirements once medical cannabis was added to his pain regimen six-weeks post-
operatively (Meng et al., 2015). His pre-operative hydromorphone requirements ranged between 
2 mg-8 mg/day, and at six week post-operatively, he was taking approximately 20-30 mg of 
hydromorphone/day and unable to resume work as an engineer because he was too drowsy from 
the opioids (Meng et al., 2015). Medical cannabis was added to his pain regimen at that point, 
and by 12 weeks post-operatively he was weaned down to 6 mg of hydrocodone/day while still 
taking the cannabis (Meng et al., 2015). He was also able to resume working because he was no 
longer too drowsy to function. In a secondary data analysis of 790 HIV-positive individuals, half 
of whom reported chronic pain, Sohler et al. (2018) found that only illicit cannabis was 
significantly (OR 0.57, CI 95%: 0.38-0.87) related to lower odds of prescription opioid use when 
compared to cigarettes, alcohol, and other illicit drugs.   
Wen and Hockenberry’s (2018) review of Medicaid data from 2011 (the first year that 
state reporting of Medicaid managed prescription data became mandatory) to 2016 (when the 
CDC issued new recommendations restricting opioid prescribing) compared the data from states 
with legalized medical and/or recreational (adult-use) cannabis to those without laws for either 
medical or adult-use cannabis. Wen and Hockenberry (2018) demonstrated that states with 
medical cannabis laws had a 5.88% lower rated of opioid prescribing (95% CI, -11.55% to -
0.21%) and states with legalized adult-use marijuana laws had a 6.38% lower rate of opioid 
prescribing (95% CI, -12.20% to -0.56%). This study was not explicitly limited to chronic pain 
patients but only evaluated opioids that had been prescribed specifically for pain.   
The findings for this Medicaid population are consistent with the review of data from 
4,840,562 commercially insured individuals between 2006 and 2014 comparing prescription 
opioid use in states with and without legal access to medical cannabis (Shah et al., 2019). Shah et 
al. (2019) found that in states where medical cannabis was legal, there was a modestly lower rate 
of acute, chronic, and high-risk opioid use compared to states without legalized medical 
cannabis. Acute opioid use was defined as at least one opioid prescription in the past year, 
chronic opioid use was defined as least 90 days of opioid use within 180 days, with no more than 
a 30-day gap in prescriptions, and high-risk opioid use was defined as a) at least one day of 
overlap between opioid and benzodiazepine prescriptions, or b) maximum daily dose > 120 
milligrams of morphine equivalents (MME), or c) diagnosis of a substance use disorder in the 
same year as the opioid prescription (Shah et al., 2019). A subgroup analysis of individuals with 
at least one non-cancer chronic pain diagnosis also showed lower risks of opioid use in states 
with legalized medical cannabis: Opioid use (Diff (95%) CI: 1.230% (1.200%-1.260%); OR 
(95% CI): 0.94 (0.92-0.05); chronic opioid use (Diff (95%) CI: 0.279% (0.275%-0.284%); OR 
(95% CI): 0.94 (0.91-0.97); high-risk opioid use (Diff (95%) CI: 0.431% (0.423%-0.440%); OR 
(95% CI): 0.91 (0.88-0.94) (Shah et al., 2019). A falsification test was also performed, finding no 
relationship between the states with medical cannabis use laws and usage of antihypertensive or 
antilipidemic drugs (Shah et al., 2019), contrary to the findings for prescription opioids.    
Within the state of New Mexico, a preliminary cohort study compared 37 chronic pain 
patients that were enrolled in the state’s Medical Cannabis Program (MCP) to 29 chronic pain 
patients using prescription opioids who did not enroll in the MCP (Vigil et al., 2017). After 21 
months of observing the Prescription Monitoring Program (PMP) records of opioid prescribing 
for these patients, MCP enrollment was associated with 17.27 higher odds of opioid prescription 
cessation (CI 1.89-157.36, p=0.012), 5.12 higher odds of decreasing daily prescription opioid 
doses (CI 1.56-16.88, p=0.007) and a 47-percentage point decrease in daily opioid doses 
compared to a mean change of positive 10.4 percentage points in the non MCP group (Vigil et 
al., 2017). Monthly trends for the MCP patients were negative over time (-0.64 mg IV morphine, 
CI -1.10 to -0.18, p=0.008) but not statistically significant for the non MCP group (Vigil et al., 
2017).   
Again, the Minnesota State Department of Health website was reviewed for information 
that may not have been discovered during the literature search. The only data found that 
examines the effect of medical cannabis on prescription opioid use is found in the report on the 
first five months that intractable pain was included as a qualifying condition in Minnesota 
(MDH, n.d.a). Of the 586 responses received from health care practitioners caring for these 
patients, 221 indicated that opioid use was reduced six months after enrolling in the medical 
cannabis program. Three hundred and fifty-three patients were known to be taking opioids at 
baseline from self-reporting, so if only those patients are considered, 221/353, or 63% were able 
to reduce or stop using opioids after six months of cannabis (MDH, n.d.a). Of the 221 patients 
who had a decrease in opioid use, 58% reduced their use of at least one opioid by 50% or more 
during the six-month period (MDH, n.d.a). A review of resources on the MDH website revealed 
a relevant article (Bradford et al., 2018) that did not appear in the database searches, possibly 
because the full text was not available within the databases searched. Bradford et al. (2018) 
completed a longitudinal analysis of daily doses of prescription opioids filled in Medicare Part D 
from 2010-2015 and compared states with medical cannabis laws (MCL) to those without MCL.  
States with active medical cannabis dispensaries saw 3.742 million fewer daily doses per year of 
opioids filled (CI 95%, -6.289 to -1.194) out of an average of 23.08 million daily doses per year.  
Results varied between types of opioid, with statistically significant negative associations for 
hydrocodone and morphine in states with MCL (Bradford et al., 2018).   
An alternative perspective was explored in the qualitative study exploring the experiences 
of adults living with chronic pain related to sickle cell disease after the implementation of the 
CDC recommendations for restricted opioid prescribing. Fifteen adults interviewed felt that the 
new restrictions had limited their access to, and amounts of, opioids prescribed to control their 
chronic pain (Sinha et al., 2019). They reported wishing to discuss other options for pain control, 
specifically cannabis, with their provider but felt their provider neglected to discuss adequate 
pain control or comprehensive care with them (Sinha et al., 2019). The patients cited difficulty 
obtaining adequate amounts of opioids, intolerable side effects associated with opioids, and a 
desire to be “off” opioids as their reasons for wanting to explore medical cannabis (Sinha et al., 
2019). These are patients who would likely intentionally decrease their opioid use in favor of 
using medical cannabis, but they lacked direction from their provider on how to explore this as 
an option.   
Like the investigation into the relationship between cannabis use and pain control, the 
same two studies that found cannabis did not improve pain control also found no association 
between using cannabis and the amounts of opioids prescribed for chronic pain patients. The 
POINT study, conducted in Australia on 1,514 patients with chronic pain taking prescription 
opioids found no evidence that cannabis use reduced the use of prescribed opiates or resulted in 
increased rates of opioid discontinuation (Campbell et al., 2018). Merlin et al. (2019) concluded 
in their study of 433 individuals living with chronic pain and HIV that cannabis use was not 
associated with either higher rates of opioid cessation or lower odds of opioid initiation. As 
mentioned in the preceding section, both studies explicitly investigated recreational cannabis use, 
which was illegal at the time of the POINT study in Australia.   
Gaps in Literature 
 The most prominent areas where the literature was lacking information was a) on the 
specific strains, types, strength, and method of ingestion of cannabis, b) explicit detail on the 
types of pain experienced by individuals experiencing chronic pain, and c) head-to-head 
comparisons effectiveness of cannabis vs. opioids is in clinical trials. Only one study 
investigated which strains of cannabis are preferred by those with chronic pain (Baron et al., 
2018); this same study noted that of the larger sample surveyed, 42 different strains were 
mentioned, giving people many options when it comes to selecting cannabis. Only the single 
case study investigated which types of pain were improved after adding cannabis (Meng et al., 
2016) by using descriptors such as “burning,” “stabbing,” etc.  ‘Pain’ can refer to many types of 
unpleasant feelings and it would be beneficial to understand what types of pain are improved by 
cannabis. None of the studies compared the effectiveness of cannabis to opioids in head-to-head 
clinical trials. The federal classification of cannabis as a Schedule 1 substance presents legal and 
logistical difficulties in accomplishing this at the present time. The Minnesota Department of 
Health also notes in their evaluation of cannabis-related studies that because most intractable, or 
chronic, pain patients are experiencing pain prior to starting cannabis, it is usually only studied 
as an adjunct treatment (MDH, n.d,a). Regardless, if feasible to study, this information would be 
helpful for both practitioners and patients in understanding what their best options may be for 
pain control.   
Discussion 
 In the middle of the opioid crisis, researching alternatives to treat pain, particularly 
chronic pain, is of utmost importance to all primary care providers, including nurse practitioners.  
The literature reviewed for this article supports the consideration of cannabis for the treatment of 
chronic pain, both for its value in relieving pain with relatively few side effects and for its role in 
potentially lowering opioid requirements. Chronic pain is multifaceted and can be debilitating.  
Nearly all studies reviewed showed that for some adults with chronic pain, control of their pain 
improved with the use of cannabis. The only two studies which did not show improvement in 
pain for adults with chronic pain after using cannabis considered cannabis use that was illegal in 
one study (Campbell et al., 2018), and either illegal or recreational in the other study, but 
specifically not prescribed medically (Merlin et al., 2019). It is important to consider that the use 
of cannabis and its effects on pain could be underreported in these two studies due to its legal 
status at the time.   
 In addition to improving pain for patients with chronic pain, it was evident in the 
literature that for some individuals, cannabis also help improve other related symptoms such as 
insomnia (Bachhuber et al., 2019; Gill & Young, 2019; MDH, n.d.b), nausea and malaise (Meng 
et al., 2016), depression (Sinha et al., 2019), concentration (Meng et al., 2016; Vigil et al., 2017) 
and anxiety (MDH, n.d.b; Sinha et al., 2016). In contrast, Campbell et al. (2018) demonstrated in 
the POINT study that patients using illicit cannabis and prescription opioids had higher 
generalized anxiety severity scores than patients taking prescription opioids who did not use 
illicit cannabis, begging the question of whether the anxiety was related to the use of an illicit 
substance. While improvement, or lack thereof, of related symptoms was not the focus of this 
literature review, they are important factors in evaluating quality-of-life for these patients.  
Except for the Campbell et al. (2018) study, all the studies that mentioned these quality-of-life 
indicators reported that they were improved with the use cannabis for adults with chronic pain.   
Perhaps even more significant were the adverse effects of taking opioids that many 
chronic pain patients reported. Negative side effects from the use of prescription opioids (Gill & 
Young, 2019; Ishida et al., 2019; Lucas et al., 2019; Meng et al., 2016; MDH, n.d.a; Sinha et al., 
2019; Zaller et al., 2015) were reported by several studies as reasons patients wished to use 
cannabis instead of opioids. Several other studies mentioned a desire by patients simply to be 
“off” opioids, whether from concerns over addiction (Gill & Young, 2019; Sinha et al., 2019; 
Zaller et al., 2015) or dislike of withdrawal symptoms (Lucas et al., 2019). Knowing that the 
American Association of Family Physicians (2016) affirmed that “regular opioid use, including 
use in an appropriate therapeutic context, is associated with both tolerance and dependence,” 
every effort should be made to consider cannabis as an alternative for controlling pain for 
individuals who chronically use opioids, especially for those who express a desire to do so.   
Several of the studies evaluated cannabis that was medically ordered, and several of the 
studies evaluated cannabis that was purchased for ‘recreational’ purposes, including at adult-use 
dispensaries (Bachhuber et al., 2019) or illicitly (Campbell et al., 2018). The advantage of 
purchasing either medical-grade cannabis or legal adult-use cannabis through dispensaries is the 
ability to purchase specific strains or types, including various THC: CBD ratios, which may be 
more helpful in controlling pain for this population. The problem with cannabis obtained through 
illicit means is that the strength and composition are usually unknown. However, regardless of 
the composition of cannabis or the source, our review suggests that for some people, it improves 
pain. The prevalence of people substituting non-medically indicated cannabis (Bachhuber et al., 
2019; Ishida et al., 2019; Sohler et al., 2018) is a testament that individuals are already exploring 
this as an option. Additional research is needed to be able to fine-tune the strain and type of 
cannabis to the type of pain and type of symptom improvement the patient needs.   
In examining substitution of cannabis for opioids, most of the studies similarly found that 
some people with chronic pain reduce their opioid use or stop using opioids altogether to control 
their pain when also taking cannabis. This held true when patients self-reported opioid use 
(Bachhuber et al., 2019; Baron et al., 2018; Ishida et al., 2019; Lucas et al., 2019; Sohler et al., 
2018; Zaller et al., 2015) and when prescription records for opioids were reviewed for patients 
either using medical cannabis or in states which allowed medical cannabis (Bradford et al., 2018; 
Meng et al., 2016; Shah et al., 2019; Vigil et al., 2017; Wen & Hockenberry, 2018). One caveat 
to consider in respect to the studies reviewing state-level data comparing opioid prescription 
rates in states with and without medical cannabis legalization is that correlation does not equal 
causation. However, this correlation held true when records were reviewed for Medicaid patients 
at the federal level (Wen & Hockenberry), Medicare Part D patients at the federal level 
(Bradford et al., 2018) and in a nationwide sample of 10% of commercially insured adults (Shah 
et al., 2019), suggesting a strong pattern of decreased opioid prescribing when medical cannabis 
is a legal option for pain control.   
The opioid-sparing effect of using cannabis for the treatment of pain may be attributed to 
a synergistic relationship between cannabis and opioids. CB1 receptors are 10 times denser than 
mu-opioid receptors in the brain, and are often found in the same areas, including those areas 
associated with pain pathways (Baron et al., 2018). Cannabis use does not increase opioid levels 
in the blood (Baron et al., 2018), reducing the concern for increased opioid side effects including 
respiratory depression. Notably, a pre-clinical study found that the median effective dose (ED50) 
of morphine given with THC is 3.6 times lower than the ED50 of morphine alone (Baron et al., 
2018). Even if the exact physiological mechanism is unknown, the evidence reviewed in this 
literature affirms that for some people with chronic pain, opioid requirements are decreased 
when used in conjunction with cannabis.   
The paucity of meta-analyses, systematic reviews, and randomized controlled studies 
available on cannabis and chronic pain is partially hampered by federal restrictions on research 
involving cannabis due to its Schedule I classification by the FDA. Level I and II evidence such 
as this would strengthen the findings of the research discussed in this review, the majority of 
which was Level IV.  
Future Implications 
Recommendations for Education 
 Both primary care providers and patients would benefit from education regarding not 
only the benefits of cannabis as a treatment option for chronic pain, but education as to the 
processes of certification, registration, and procurement of cannabis. Sickle cell patients with 
chronic pain felt that their providers were focused on reducing the amounts of opioids 
prescribed, but neglected to discuss adjunct or alternative therapies, including cannabis, during 
appointments (Sinha et al., 2019). The benefits of using for cannabis for the treatment of chronic 
pain are detailed in the previous sections, but the logistics of obtaining medical cannabis merits 
explanation.   
 In Minnesota, cannabis is legally available for treatment of 15 medical conditions, 
including intractable pain and chronic pain (MDH, n.d.b). For a patient to obtain medical 
cannabis, a physician, PA, or APRN must conduct a physical examination, review of pertinent 
records, and certify the patient as having a qualifying condition (Institute for Clinical Systems 
Improvement [ICSI], 2015). The provider only certifies that the patient has a qualifying 
condition under state law, they do not “prescribe” cannabis. A provider must be registered with 
the state of Minnesota’s Office of Medical Cannabis (OMC) to certify a patient as having a 
qualifying condition. The patient, once certified, also registers with the OMC. After paying an 
enrollment fee, they can visit one of the 13 Cannabis Patient Centers located throughout the state 
to meet with a licensed pharmacist to determine the best dose, type, and frequency based on the 
patient’s condition and symptoms (ICSI, 2015), and the cannabis is dispensed to the patient.  
Patients wishing to continue using medical cannabis must be re-certified annually by a registered 
provider. Providing education to all primary care providers regarding this process would help 
guide discussion with their patients regarding cannabis as an option for pain control.  
Information for providers and patients is available on the Minnesota Department of Health’s 
website on this process (ICSI, 2015) but it is unknown how widely this information has been 
disseminated. 
Recommendations for Clinical Practice 
 In accordance with the 2016 CDC guidelines suggesting opioids not be used as a first-line 
treatment for patients with chronic pain (Dowell, 2016), primary care providers, including nurse 
practitioners, should be familiar with the use of cannabis as an alternative to or in conjunction 
with opioids. They also need to be familiar with the process of registering as a provider and 
certifying patients with the OMC so that they can effectively address the needs of their patients 
with chronic pain. Since the MDH does not maintain a list of providers who are registered with 
the OMC, there is no way for patients to know in advance of their appointment whether their 
primary care provider can certify them for medical cannabis.   
 In Minnesota in 2019, there were 24,643 physicians with active state licenses, 3209 
actively licensed physician assistants (PAs), and 8,849 actively licensed Advanced Practice 
Registered Nurses (APRNs) for a total of 36,701 licensed providers (MDH, 2019c; MDH 2019d; 
MDH, 2019e). However, as of March 11, 2020, only 1,865 of these providers were registered 
with the OMC and eligible to certify patients for medical cannabis (MDH, 2021). This represents 
only 5% of all licensed providers in the state of Minnesota. In the first five months that 
intractable pain was included as a certifiable condition in Minnesota, only 9% of the 265 
providers certifying these intractable pain patients were APRNs (MDH, n.d.a). Of the 226 
physicians certifying patients for intractable pain during that timeframe 52% listed a specialty in 
primary care or family medicine (MDH, n.d.a). The impetus is on providers, particular in 
primary care and nurse practitioners, to register with the OMC within this state so that they can 
certify patients with chronic or intractable pain that could potentially benefit from medical 
cannabis. They should also be knowledgeable about the effects of cannabis, both beneficial and 
adverse, so they can have evidence-based discussions with their patients about the best approach 
to manage their pain. 
Recommendations for Policies 
 The most important policy concern related to using cannabis as a treatment for pain is its 
FDA classification as a Schedule I controlled substance. To legitimize cannabis as a valid 
medical treatment, its classification must reflect the existing evidence showing benefit from its 
use in controlling pain for patients with chronic pain, and therefore be changed. The 
classification of cannabis as a Schedule I controlled substance currently hampers the ability to 
research it, even within states that allow for legal medical use of it. Providers are placed in an 
undesirable position of certifying a patient for a condition for a legal treatment at the state level, 
knowing it is not FDA approved or even legal at the federal level. The fear of using something 
deemed illegal at the federal level may also deter patients who would otherwise consider 
cannabis as an option for controlling pain. Even individuals who use cannabis for medical 
purposes in states where it is legal are prohibited from owning firearms by the federal 
government due to cannabis’ status as a Schedule I controlled substance (MDH, n.d.c). Because 
opioids are classified as Schedule II and lower, there are no limitations on firearm possession if 
an adult is prescribed an opioid. Individuals with chronic pain are more likely to reside in rural 
areas (Zelaya et al., 2020), a demographic often associated with increased rates of firearm 
possession, so limitations on their rights to bear arms may be a considerable factor in deciding 
whether to use medical cannabis for those who may need it the most.   
 Another policy revision that merits consideration is the legalization of cannabis for adult-
use, or recreational use, in addition to medical use. Based on the patterns noted in the research of 
the use of recreational marijuana to treat pain (Bachhuber et al., 2018) and self-substitution of 
cannabis for opioids with non-medical cannabis (Ishida et al., 2019; Sinha et al., 2019; Sohler et 
al., 2018), it is an idea that may warrant careful appraisal. With only five percent of current 
providers in Minnesota registered to certify conditions for medical cannabis, and no centralized 
listing to access the providers who are certified, the barriers to obtaining medical cannabis are 
self-evident (MDH, 2019c; MDH, 2019d; MDH, 2019e). Medical cannabis is not covered by 
insurance in the state of Minnesota (MDH, n.d.c), so persons using medical cannabis are paying 
face value for their cannabis even though it requires at least one visit to a provider for initial 
certification, a $200 enrollment fee in the Medical Cannabis Program, and annual visits to a 
provider to be re-certified (MDH, n.d.c). If the cost is the same to the individual regardless of 
whether it is deemed medical or not, opening cannabis up to recreational use may remove some 
of these barriers preventing chronic pain patients from exploring this as an option.   
 Following from this, if medical cannabis is to be considered a legitimate treatment for 
pain, it should also be covered both by federal and state programs, including Medicare and 
Medicaid, and private insurance companies as such. Opioids are covered under most insurance, 
so cost and accessibility at the present time may dissuade patients who could benefit from 
cannabis from considering this as an alternative or adjunct to chronic opioid use. For example, 
generic oxycodone costs anywhere from a $0-$20 co-pay under Medicare with 99% of Medicare 
Part D and Medicare Advantage plans covering it (GoodRx, 2020). By contrast, no insurance 
companies in the state of Minnesota currently cover medical cannabis. If providers are 
recommending alternatives to opioids for controlling pain in patients with chronic pain, it 
follows that those alternatives should be covered similarly to the coverage of opioids.   
 
Recommendations for Research 
 As discussed earlier, further research is indicated in three primary areas for which the 
literature is lacking. The first is specificity relating to cannabis composition and method of 
ingestion to best match specific symptoms of pain to the most effective type of cannabis. Baron 
et al. (2018) began exploring this in their investigation of preferred strains of cannabis for 
chronic pain patients, and if cannabis is to be considered as a valid treatment for pain, it merits 
the same kind of research into how best to achieve that as other pharmaceutical options have 
done in the past. The second area in which further research is indicated is to further differentiate 
what specific types of pain are improved with cannabis. Meng et al. (2016) detailed this in a case 
study, but this type of research needs to be extended to large studies investigating sub-types of 
pain and their response to cannabis. The third area in which a strong indication for additional 
research is present is the need for randomized clinical trials comparing cannabis directly to 
opioids to determine what is the most effective means of controlling pain. The evidence 
reviewed above strongly suggests that cannabis not only helps improve pain in some people, but 
also allows some people to decrease the amounts of opioids necessary to control their pain.  
Except for personal experiences recounted during some of the qualitative studies (MDH, n.d.b; 
Sinha et al., 2019; Zaller et al., 2015), none of the studies examined the efficacy of opioids 
compared to cannabis. Particularly absent is the availability of data from RCTs which would 
give additional insight into which treatment is more effective. Legal and ethical limitations 
prohibit this from being easily accomplished at the present time.   
 Research is also needed to determine what the potential adverse effects of cannabis are 
when used as a treatment for chronic pain. Examining this in detail exceeds the scope of this 
paper, but it is an important consideration in recommending cannabis as a treatment.  Even 
though no deaths have definitively been linked to an overdose of cannabis or cannabinoids it is 
known that multiple adverse effects may occur, including impairment of judgement, memory, 
motor skills and driving ability (Incze et al., 2020). It is also known that, like opioids, cannabis 
use can be habit-forming over time (Incze et al., 2020) although this is usually examined in 
context of recreational use. Research on not only the positive, but negative effects of medical 
cannabis in both the short and long term would help clinicians feel more confident in 
recommending this as a treatment.   
 As the data from Minnesota suggests, few providers are registered to certify patients with 
conditions allowing them to access medical cannabis. Research into what barriers exist to 
prevent providers from registering with the OMC in Minnesota would be helpful in widening the 
circle of providers who are able to recommend this as an option for patients with chronic pain.  
Conclusion 
 A review of the most recent literature suggests that in adults with chronic pain, cannabis 
both improves control of pain and reduces the amounts of opioids necessary to control pain in 
some individuals. With the 2016 CDC recommendation that opioids should not be a first line 
treatment for chronic pain (Dowell et al., 2016), cannabis could and should be considered by 
primary care providers, including nurse practitioners, as a viable alternative to or adjunct to 
opioids for control of pain in this population. Changing the federal classification of cannabis 
from a Schedule I controlled substance to one that more accurately reflects its medical value 
would increase research opportunities and improve access for many adults who may benefit from 
cannabis as a treatment for chronic pain. Health care providers, particularly nurse practitioners 
and those working in primary care, should be familiar with the associated provider registration 
and patient certification processes related to providing access to medical cannabis for their 
patients who could benefit from it. 
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opioid discontinuation. 
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evidence that 
marijuana use in 
PLWH and 



















R. & Liebschutz, J. M. 
(2019). Marijuana use is 
not associated with 
changes in opioid 
prescriptions or pain 
severity among people 
living with HIV and 
chronic pain. J Acquir 



















































Changes in pain 
and initiation or 
discontinuation 
of opioids 





Shah, A., Hayes, C. J., 
Lakkad, M., & Martin, B. 
C. (2019). Impact of 
medical marijuana 
legalization on opioid 
use, chronic opioid use, 
and high-risk opioid use. 
















p= A 10% 
























were in effect 






In the fully adjusted analyses, 
MML was associated with a 
lower probability of opioid use, 
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Participants reported that 
recently their opioid 
prescriptions had become more 
restrictive, were more closely 
monitored, and were 
increasingly difficult to fill in 
pharmacies. Participants also 
described increased 
stigmatization about opioid use 
and that their medical care was 
being affected by the 
physician’s exclusive focus on 
reducing pain medication use. 
There was an emerging interest 
among adult patients in the 
consideration of the use of 
alternative therapies, including 
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Level IV   
I: Interview 
questionnaire 




private setting in 
office or over 
phone.   
V: Outcome: 
Current use of a 
Analysis of cigarette, alcohol, 
and illicit drug use patterns 
found that only cannabis use 
was independently associated 
with prescribed opioid 
analgesic use after adjusting 
for potential confounders and 
other substance use. Compared 
with nonusers, those who 
reported cannabis use 
were significantly less likely to 
report prescribed opioid 
Findings 
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opioid analgesic.  
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reviewed over a 
21-month period  
to measure 
cessation 
and reduction.  
MCP patient- 
reported 
benefits and  
side-effects of 
using cannabis 












enrollment and opioid 
prescription cessation and 
reduction. Survey responses 
indicated improvements in pain 
reduction, quality of life, social 
life, activity levels, and 
concentration, and few side 
effects from using cannabis one 
year after enrolling in the MCP. 
use and 
improved 
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measured as the 
number of 
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State implementation of 
medical marijuana laws was 
associated with a 5.88% lower 
rate of opioid prescribing. The 
implementation of adult-use 
marijuana laws, which all 
occurred in states with existing 
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prescribing rate 


































































Medicaid on a 
quarterly, per-
1000-Medicaid-
enrollee basis.  
Exposure: State 
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medical marijuana laws, was 
associated with a 6.38% lower 
rate of opioid prescribing. 
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using the Brief 
69% of participants reported 
experiencing chronic pain and 
described feeling “much better” 
with the use of medicinal 
marijuana (85%).  92% 
The majority of 
study 
participants 
sought to obtain 
relief from 
chronic pain and 








































considered medicinal marijuana 
to have fewer unwanted 
side-effects than conventionally 
prescribed pain management 
medications. >50% of 
participants reported using 
cannabis in place of 
prescription drugs or were 
making serious attempts to 
wean off high doses of 
prescription drugs, such as 






use of medicinal 
cannabis. Most 
patients 
interviewed 
report that 
medicinal 
cannabis 
improves their 
pain 
symptomology, 
and are 
interested in 
alternative 
treatment 
options to 
opioid-based 
treatment 
regimens. 
 
